CTOs on the Move

Biohaven Pharmaceutical

www.biohavenpharma.com

 
Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Biohaven Pharmaceutical raised $80M on 11/01/2016
Biohaven Pharmaceutical raised $80M on 07/03/2017
Biohaven Pharmaceutical raised $200M on 03/15/2021

Similar Companies

PharmaForm

PharmaForm is a leading specialty contract development and manufacturing organization focusing on oral and transmucosal dosage forms. Founded in 1996, PharmaForm has built a reputation for delivering novel and innovative solutions to challenging problems

Tesaro

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics.

Kirkegaard and Perry Laboratories

KPL is committed to protecting the privacy of our customers. Our Privacy Policy covers any personal information that KPL.com obtains from you when you use services on our site. We use this information to enhance our services and to make them more

Unlearn

Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.

Clemson University Biomedical Engineering Innovation Campus

The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.